Ingo Janssen1,2, Clara C Chen3, Zhenping Zhuang4, Corina M Millo5, Katherine I Wolf1, Alexander Ling6, Frank I Lin7, Karen T Adams1, Peter Herscovitch5, Richard A Feelders8, Antonio T Fojo9, David Taieb10, Electron Kebebew11, Karel Pacak12. 1. Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. 2. Department of Radiology and Nuclear Medicine, Section of Nuclear Medicine, University Hospital Schleswig Holstein, Lübeck, Germany. 3. Nuclear Medicine Division, Radiology & Imaging Sciences, National Institutes of Health, Bethesda, Maryland. 4. Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland. 5. Positron Emission Tomography Department, National Institutes of Health, Bethesda, Maryland. 6. Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, Maryland. 7. Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 8. Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. 9. Endocrine Oncology Branch, National Cancer Institute, Bethesda, Maryland. 10. Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France; and. 11. Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. 12. Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland karel@mail.nih.gov.
Abstract
Pheochromocytoma/paraganglioma (PPGL) syndromes associated with polycythemia have previously been described in association with mutations in the von Hippel-Lindau gene. Recently, mutations in the prolyl hydroxylase gene (PHD) 1 and 2 and in the hypoxia-inducible factor 2 α (HIF2A) were also found to be associated with multiple and recurrent PPGL. Such patients also presented with PPGL and polycythemia, and later on, some presented with duodenal somatostatinoma. In additional patients presenting with PPGL and polycythemia, no further mutations have been discovered. Because the functional imaging signature of patients with PPGL-polycythemia syndromes is still unknown, and because these tumors (in most patients) are multiple, recurrent, and metastatic, the goal of our study was to assess the optimal imaging approach using 4 different PET radiopharmaceuticals and CT/MRI in these patients. Methods: Fourteen patients (10 women, 4 men) with confirmed PPGL and polycythemia prospectively underwent 68Ga-DOTATATE (13 patients), 18F-FDG (13 patients), 18F-fluorodihydroxyphenylalanine (18F-FDOPA) (14 patients), 18F-fluorodopamine (18F-FDA) (11 patients), and CT/MRI (14 patients). Detection rates of PPGL lesions were compared between all imaging studies and stratified between the underlying mutations. Results: 18F-FDOPA and 18F-FDA PET/CT showed similar combined lesion-based detection rates of 98.7% (95% confidence interval [CI], 92.7%-99.8%) and 98.3% (95% CI, 90.9%-99.7%), respectively. The detection rates for 68Ga-DOTATATE (35.3%; 95% CI, 25.0%-47.2%), 18F-FDG (42.3; 95% CI, 29.9%-55.8%), and CT/MRI (60.3%; 95% CI, 48.8%-70.7%) were significantly lower (P < 0.01), irrespective of the mutation status. Conclusion: 18F-FDOPA and 18F-FDA are superior to 18F-FDG, 68Ga-DOTATATE, and CT/MRI and should be the radiopharmaceuticals of choice in this rare group of patients.
Pheochromocytoma/paraganglioma (PPGL) syndromes associated with polycythemia have previously been described in association with mutations in the von Hippel-Lindau gene. Recently, mutations in the prolyl hydroxylase gene (PHD) 1 and 2 and in the hypoxia-inducible factor 2 α (HIF2A) were also found to be associated with multiple and recurrent PPGL. Such patients also presented with PPGL and polycythemia, and later on, some presented with duodenal somatostatinoma. In additional patients presenting with PPGL and polycythemia, no further mutations have been discovered. Because the functional imaging signature of patients with PPGL-polycythemia syndromes is still unknown, and because these tumors (in most patients) are multiple, recurrent, and metastatic, the goal of our study was to assess the optimal imaging approach using 4 different PET radiopharmaceuticals and CT/MRI in these patients. Methods: Fourteen patients (10 women, 4 men) with confirmed PPGL and polycythemia prospectively underwent 68Ga-DOTATATE (13 patients), 18F-FDG (13 patients), 18F-fluorodihydroxyphenylalanine (18F-FDOPA) (14 patients), 18F-fluorodopamine (18F-FDA) (11 patients), and CT/MRI (14 patients). Detection rates of PPGL lesions were compared between all imaging studies and stratified between the underlying mutations. Results:18F-FDOPA and 18F-FDA PET/CT showed similar combined lesion-based detection rates of 98.7% (95% confidence interval [CI], 92.7%-99.8%) and 98.3% (95% CI, 90.9%-99.7%), respectively. The detection rates for 68Ga-DOTATATE (35.3%; 95% CI, 25.0%-47.2%), 18F-FDG (42.3; 95% CI, 29.9%-55.8%), and CT/MRI (60.3%; 95% CI, 48.8%-70.7%) were significantly lower (P < 0.01), irrespective of the mutation status. Conclusion:18F-FDOPA and 18F-FDA are superior to 18F-FDG, 68Ga-DOTATATE, and CT/MRI and should be the radiopharmaceuticals of choice in this rare group of patients.
Authors: Henri J L M Timmers; Anna Kozupa; Graeme Eisenhofer; Margarita Raygada; Karen T Adams; Daniel Solis; Jacques W M Lenders; Karel Pacak Journal: J Clin Endocrinol Metab Date: 2007-01-02 Impact factor: 5.958
Authors: Nelly Burnichon; Alberto Cascón; Francesca Schiavi; Nicole Paes Morales; Iñaki Comino-Méndez; Nasséra Abermil; Lucía Inglada-Pérez; Aguirre A de Cubas; Laurence Amar; Marta Barontini; Sandra Bernaldo de Quirós; Jérôme Bertherat; Yves-Jean Bignon; Marinus J Blok; Sara Bobisse; Salud Borrego; Maurizio Castellano; Philippe Chanson; María-Dolores Chiara; Eleonora P M Corssmit; Mara Giacchè; Ronald R de Krijger; Tonino Ercolino; Xavier Girerd; Encarna B Gómez-García; Alvaro Gómez-Graña; Isabelle Guilhem; Frederik J Hes; Emiliano Honrado; Esther Korpershoek; Jacques W M Lenders; Rocío Letón; Arjen R Mensenkamp; Anna Merlo; Luigi Mori; Arnaud Murat; Peggy Pierre; Pierre-François Plouin; Tamara Prodanov; Miguel Quesada-Charneco; Nan Qin; Elena Rapizzi; Victoria Raymond; Nicole Reisch; Giovanna Roncador; Macarena Ruiz-Ferrer; Frank Schillo; Alexander P A Stegmann; Carlos Suarez; Elisa Taschin; Henri J L M Timmers; Carli M J Tops; Miguel Urioste; Felix Beuschlein; Karel Pacak; Massimo Mannelli; Patricia L M Dahia; Giuseppe Opocher; Graeme Eisenhofer; Anne-Paule Gimenez-Roqueplo; Mercedes Robledo Journal: Clin Cancer Res Date: 2012-03-27 Impact factor: 12.531
Authors: G Eisenhofer; D Hovevey-Sion; I J Kopin; R Miletich; K L Kirk; R Finn; D S Goldstein Journal: J Pharmacol Exp Ther Date: 1989-01 Impact factor: 4.030
Authors: Henri J L M Timmers; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Graeme Eisenhofer; Kathryn S King; Jyotsna U Rao; Robert A Wesley; Karen T Adams; Karel Pacak Journal: J Natl Cancer Inst Date: 2012-04-18 Impact factor: 13.506
Authors: Ingo Janssen; Clara C Chen; David Taieb; Nicholas J Patronas; Corina M Millo; Karen T Adams; Joan Nambuba; Peter Herscovitch; Samira M Sadowski; Antonio T Fojo; Inga Buchmann; Electron Kebebew; Karel Pacak Journal: J Nucl Med Date: 2015-11-12 Impact factor: 10.057
Authors: David Taïeb; Rodney J Hicks; Elif Hindié; Benjamin A Guillet; Anca Avram; Pietro Ghedini; Henri J Timmers; Aaron T Scott; Saeed Elojeimy; Domenico Rubello; Irène J Virgolini; Stefano Fanti; Sona Balogova; Neeta Pandit-Taskar; Karel Pacak Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-29 Impact factor: 9.236
Authors: Edward P Lin; Bennett B Chin; Lauren Fishbein; Toshio Moritani; Simone P Montoya; Shehanaz Ellika; Shawn Newlands Journal: Radiol Imaging Cancer Date: 2022-05